Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Sep 4, 2024
Discovery & Translation
Immunoproteomics upstage genomics in I&I target discovery
Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them
BioCentury | Jun 14, 2024
Finance
Venture Report: Clinical plays Alzheon, Bright Peak raise growth capital
Plus: Early-stage financings for InduPro, Syntis and Moleculent; J.P. Morgan closes its life sciences vehicle; and a new fund for spinal injury
BioCentury | Jun 6, 2024
Product Development
Solid tumor immunotherapies headline ASCO’s first-in-human studies
A focus on first-in-class innovation and solid tumor applications
BioCentury | May 23, 2024
Emerging Company Profile
Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome
Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assembly
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
BioCentury | Jan 30, 2024
Finance
Biotech IPOs & momentum in the IL-18 field: BioCentury’s latest podcast
Plus: the schizophrenia pipeline and what’s next for Singapore biotech
BioCentury | Jan 26, 2024
Product Development
Growing IL-18 field looks to enhance cell therapies via decoy evasion
As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
Items per page:
1 - 10 of 80